SGLT2i, Pioglitazone, and Ketone Production in T1D (NCT07056699)
Protocol V: San Antonio Site Sub Study: Can Pioglitazone Block SGLT2 Inhibitor-induced Stimulation of Lipolysis, Ketone Production and Liver Glucose Production in Type I Diabetic Patients
🩺 Plain-English Summary (8th-Grade Level)
Participants are being asked to be in a research study. Scientists do research to answer important questions which might help change or improve treatment of participants disease in the future. In patients with Type 1 Diabetes (T1D), dapagliflozin a Selective Glucose Transporter 2 Inhibitor (SGLT2i) is known to increase production of glucose in the liver, increase breakdown of fats (lipolysis), and increase production of ketones (ketogenesis). Ketones are chemicals produced by the liver when the body breaks down fat for energy instead of glucose. When the level of ketones in the body becomes too high, a condition called ketoacidosis develops. In this study, the study team will investigate whether adding pioglitazone (a medication commonly used to treat type 2 diabetes), can reduce the dapagliflozin - induced liver glucose production, fat break down (lipolysis) and ketone body production (ketogenesis) in patients with T1D.
Who can join: Review the eligibility criteria below.
Location: Texas Diabetes Institute — San Antonio, Texas
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Texas Diabetes Institute — San Antonio, Texas
📞 Contact the Study Coordinator
Phone: (210) 567-6691
Email: defronzo@uthscsa.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Type1diabetes
- Physiologic Markers of Cardiometabolic Risk in People With Type 1 Diabetes — New Haven, Connecticut
- REACHOUT Mental Health Support Mobile App — Vancouver, British Columbia
- Pancreas Ultrasound Imaging in type1 Diabetes — Aurora, Colorado
- Effects of Ketosis on Brain Function in Patients With T1DM — Boston, Massachusetts
- Genetics Of Autoimmunity In Type I Diabetes — Milwaukee, Wisconsin
- Glycemic Variations During the Menstrual Cycle in Women With Type 1 Diabetes — Montreal, Quebec
Explore by condition: All Type1diabetes clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.